Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells

American Journal of Pathology

Volumn 169, Issue 2, 2006, Pages 682-696

  Yuan, Xin ^a,b   Li, Tong ^a   Wang, Hongyun ^a   Zhang, Tao ^a   Barua, Moumita ^a   Borgesi, Robert A ^a   Bubley, Glenn J ^a   Lu, Michael L ^a   Balk, Steven P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MITOGEN ACTIVATED PROTEIN KINASE; RETINOBLASTOMA PROTEIN;

ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER RELAPSE; CASTRATION; CELL CYCLE; CELL STRAIN CWR22; CONTROLLED STUDY; ENZYME ACTIVATION; GENE; GENETIC TRANSFECTION; GROWTH INHIBITION; HORMONAL THERAPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PSA GENE; REPORTER GENE; TRANSCRIPTION REGULATION; XENOGRAFT;

EID: 33746661499     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.051047     Document Type: Article

References (50)

1. Gelmann EP: Molecular biology of the androgen receptor. J Clin Oncol 2002, 20:3001-3015
2. Feldman BJ, Feldman D: The development of androgen-independent prostate cancer. Nature Rev Cancer 2001, 1:34-45
3. Balk SP: Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002, 60:132-138
4. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ: High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998, 159:149-153
5. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini Bi, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ: Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004, 22:1025-1033
6. Kokontis JM, Hay N, Liao S: Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998, 12:941-953
7. Gregory CW, Johnson Jr RT, Mohler JL, French FS, Wilson EM: Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001, 61:2892-2898
8. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ: Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002, 62:1008-1013
9. Wright ME, Tsai MJ, Aebersold R: Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 2003, 17:1726-1737
10. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL: Molecular determinants of resistance to anti-androgen therapy. Nat Med 2004, 10:33-39
11. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE: Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 2005, 96:251-258
12. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995, 332:1393-1398
13. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995, 9:401-406
14. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H: Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993, 7:1541-1550
15. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, Feldman D: Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol 1999, 162:2192-2199
16. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP: Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999, 59:2511-2515
17. Taplin ME, Rajeshkumar B, Haiabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ: Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003, 21:2673-2678
18. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM: A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001, 61:4315-4319
19. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, Wilson EM: Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004, 279:7119-7130
20. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ: Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003, 63:1981-1989
21. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL: HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004, 6:517-527
22. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M: Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997, 15:2928-2938
23. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, Edgehouse NL, Pretlow TP, Bodner DR, Kursh ED: CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994, 54:6049-6052
24. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG: CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996, 56:3042-3046
25. Yuan X, Lu ML, Li T, Balk SP: SRY interacts with and negatively regulates androgen receptor transcriptional activity. J Biol Chem 2001, 276:46647-46654
26. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP: Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002, 277:26321-26326
27. Kochera M, Depinet TW, Pretlow TP, Giaconia JM, Edgehouse NL, Pretlow TG, Schwartz S: Molecular cytogenetic studies of a serially transplanted primary prostatic carcinoma xenograft (CWR22) and four relapsed tumors. Prostate 1999, 41:7-11
28. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS: Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 1998, 58:5718-5724
29. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Koivenbag G, Bubley GJ, Balk SP: Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997, 3:1383-1388
30. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, DeVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS: Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997, 11:450-459
31. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Weber MJ: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999, 59:279-284
32. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR: Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999, 59:4291-4296
33. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R: Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003, 34:263-264
34. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, Wolfsberg TG, Umayam L, Lee JC, Hughes CM, Shanmugam KS, Bhattacharjee A, Meyerson M, Collins FS: Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci USA 2004, 101:1892-1897
35. Chen Y, Robles AI, Martinez LA, Liu F, Gimenez-Conti IB, Conti CJ: Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ 1996, 7:1571-1578
36. Knudsen KE, Arden KC, Cavenee WK: Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem 1998, 273:20213-20222
37. Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattacharya N, Cirenei N, Loda M: Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol 2001, 15:765-782
38. Gregory CW, Johnson Jr RT, Presnell SC, Mohler JL, French FS: Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft J Androl 2001, 22:537-548
39. Chen Y, Martinez LA, LaCava M, Coghlan L, Conti CJ: Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene 1998, 16:1913-1920
40. Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato AC: Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 1999, 18:6322-6329
41. Castoria G, Lombardi M, Barone MV, Bilancio A, Di Domenico M, de Falco A, Varricchio L, Bottero D, Nanayakkara M, Migliaccio A, Auricchio F: Rapid signalling pathway activation by androgens in epithelial and stromal cells. Steroids 2004, 69:517-522
42. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC: Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001, 104:719-730
43. Castoria G, Lombardi M, Barone MV, Bilancio A, Di Domenico M, Bottero D, Vitale F, Migliaccio A, Auricchio F: Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action. J Cell Biol 2003, 161:547-556
44. Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ: Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem 2003, 278:42992-43000
45. Baron S, Manin M, Beaudoin C, Leotoing L, Communal Y, Veyssiere G, Morel L: Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J Biol Chem 2004, 279:14579-14586
46. Hammes SR: Steroids and oocyte maturation - a new look at an old story. Mol Endocrinol 2004, 18:769-775
47. Yeh S, Miyamoto H, Nishimura K, Kang H, Ludlow J, Hsiao P, Wang C, Su C, Chang C: Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. Biochem Biophys Res Commun 1998, 248:361-367
48. Lu J, Danielsen M: Differential regulation of androgen and glucocorticoid receptors by retinoblastoma protein. J Biol Chem 1998, 273:31528-31533
49. Knudsen KE, Cavenee WK, Arden KC: D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res 1999, 59:2297-2301
50. Liao X, Tang S, Thrasher JB, Griebling TL, Li B: Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 2005, 4:505-515